Dilip Shanghvi, Sun Pharma founder

Sun Phar­ma shelling out $485M to set­tle US an­titrust case against gener­ics gi­ant

Sun Phar­ma has agreed to a big pay­out to set­tle claims of mis­con­duct lev­eled against its Ran­baxy gener­ics unit.

Just ahead of a tri­al over long-sim­mer­ing al­le­ga­tions that Ran­baxy had schemed to mus­cle ahead of ri­vals and hit the mar­ket with 3 ex­clu­sive knock­offs of some of the biggest med­i­cines of the time, Sun has agreed to shell out $485 mil­lion to set­tle the class ac­tion suit, with­out ad­mit­ting to the charges.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.